RSS Feeds
Octreotide Therapy for the Sjögren Syndrome
- Tri G. Phan, FRACP, FRCPA;
- Tom P. Gordon, FRACP, FRCPA, PhD;
- Martin H.N. Tattersall, FRACP, MD; and
- Robert H. Loblay, FRACP, PhD
- Royal Prince Alfred Hospital; Camperdown, NSW 2050, Australia Flinders Medical Centre and Flinders University; Bedford Park, SA 5042, Australia University of Sydney; Newtown, NSW 2006, Australia
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: The Sjögren syndrome is a systemic autoimmune disease characterized by focal lymphocytic infiltration …
This 100-word excerpt has been provided in the absence of an abstract.
